chitosan has been researched along with osimertinib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S; Duan, Y; Hu, X; Jiang, L; Wang, Q; Yin, H; Zhao, L | 1 |
| Chen, S; Ji, X; Jin, J; Zhang, H; Zhao, L; Zhao, M | 1 |
| Aalhate, M; Dhuri, A; Gupta, U; Guru, SK; Mahajan, S; Maji, I; Parida, KK; Singh, H; Singh, PK; Sriram, A | 1 |
3 other study(ies) available for chitosan and osimertinib
| Article | Year |
|---|---|
Chitooligosaccharides-modified PLGA nanoparticles enhance the antitumor efficacy of AZD9291 (Osimertinib) by promoting apoptosis.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Apoptosis; B7-H1 Antigen; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Caspase 9; Cell Line, Tumor; Cell Survival; Chitin; Chitosan; Drug Carriers; Drug Liberation; ErbB Receptors; Humans; Inhibitory Concentration 50; Microscopy, Electron, Transmission; Nanoparticles; Oligosaccharides; Particle Size; Poly (ADP-Ribose) Polymerase-1; Polylactic Acid-Polyglycolic Acid Copolymer; Proto-Oncogene Proteins c-bcl-2 | 2020 |
Construction of chitooligosaccharide-based nanoparticles of pH/redox cascade responsive for co-loading cyclosporin A and AZD9291.
Topics: Acrylamides; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chitosan; Cyclosporine; Drug Delivery Systems; Humans; Hydrogen-Ion Concentration; Indoles; Lung Neoplasms; Nanoparticles; Oligosaccharides; Oxidation-Reduction; Pyrimidines; Tumor Microenvironment | 2022 |
Chitosan functionalized PCL nanoparticles bearing tyrosine kinase inhibitor osimertinib mesylate for effective lung cancer therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Chitosan; Drug Carriers; Humans; Lung; Lung Neoplasms; Nanoparticles; Polyesters; Tyrosine Kinase Inhibitors | 2023 |